Elevai Labs, Inc. - ELAB STOCK NEWS

Elevai Labs, Inc. (NASDAQ: ELAB), a leader in medical aesthetics, has announced an exchange offer for up to 15,000,000 shares of its common stock. Shareholders can exchange their common stock for newly issued Series B Preferred Stock on a one-for-one basis. The offer expires on November 5, 2024, at 5:00 P.M. New York City Time, unless extended or withdrawn.

Key points:

• Stockholders must tender all of their common stock to participate
• The exchange is subject to terms and conditions in the Offer to Exchange dated October 4, 2024
• Full details are available in the Offer Documents and Schedule TO filed with the SEC

Elevai Labs, Inc. (NASDAQ: ELAB) has announced the filing of two new patent applications for its lead candidate, EL-22, targeting muscle loss treatment in obese patients. These applications cover EL-22 as a monotherapy and in combination with GLP-1 receptor agonists. EL-22, an engineered probiotic expressing myostatin, aims to preserve muscle mass while reducing fat mass during obesity treatment.

The company has completed a Phase 1 clinical trial in South Korea, demonstrating EL-22's safety and tolerability. Elevai plans to assess its efficacy in combination with leading weight-loss therapies to address muscle wasting, a common side effect of GLP-1 medications. With these new filings, Elevai Biosciences' patent portfolio now includes 4 patent applications and 5 issued patents, providing protection in key markets such as the USA, Japan, China, and Korea.

Elevai Labs, Inc. (NASDAQ: ELAB) has announced the launch of a clinical study to evaluate the efficacy of its topical exosome products, Elevai empower™ and Elevai enfinity™, in combination with energy device treatments for facial skin rejuvenation. The study, conducted in collaboration with Dr. Jennifer Pearlman, aims to enroll up to 20 subjects aged 35-75 with various skin conditions.

The 12-week study will assess the products' efficacy as standalone treatments and in conjunction with energy devices, measuring tolerability, safety, and improvements in overall facial appearance. Elevai expects to announce topline data by Q1 2025 and publish results in a peer-reviewed journal.

This initiative aligns with the growing energy-based aesthetic device market, projected to reach $5.60 billion by 2030. Elevai is actively seeking partnerships with energy device companies to explore synergistic opportunities in the field of non-invasive skin rejuvenation.

Elevai Labs, Inc. (NASDAQ: ELAB), a medical aesthetics company, has announced the pricing of a $8.0 million public offering. The offering includes 28,571,425 shares of common stock (or pre-funded warrants) at $0.28 per share. Each share comes with two warrants: a Series A Warrant and a Series B Warrant, both exercisable at $0.38 per share. The Series A Warrants expire after five years, while the Series B Warrants expire after two and a half years from the Initial Exercise Date. Univest Securities, is the sole placement agent. The offering is expected to close around September 24, 2024. Elevai plans to use the net proceeds for general corporate purposes, including working capital and investments.

Elevai Labs Inc. (NASDAQ: ELAB) has announced positive case study results for its E-Series exosome technology in potential melasma applications. The study, conducted by Dr. Chau Ngoc To Trinh in Vietnam, involved four female patients with moderate to severe mixed type melasma. A triple combination method was used, including Er:YAG and Nd:YAG lasers, followed by Elevai's topical exosome products.

Key findings include:

• Significant improvement after two months of treatment
• No melasma recurrence after six months
• Potential synergistic effects between laser therapy and exosome products

The global melasma treatment market is expected to grow from $2.85 billion in 2022 to $4.83 billion by 2030, with a CAGR of 6.8%. Elevai plans to conduct larger studies to further demonstrate the potential of combining their exosome products with laser therapy for melasma treatment.

Elevai Labs, Inc. (NASDAQ: ELAB) has announced promising results from an ongoing research study on hair restoration using their proprietary Elevai Exosomes™ technology. The study, conducted in partnership with the National Hair Loss Medical Aesthetics (NHLMA), demonstrated potential benefits for individuals experiencing hair loss or thinning.

Key findings include:

• Ceased crown inflammation
• Reversal of miniaturized hairs
• Recovery of dormant hair

The treatment involved scalp microneedling with Elevai empower™ in-office, followed by at-home use of Elevai enfinity™. Elevai is now conducting further research on their new S-Series Root Renewal System™, which combines exosome and mitochondrial technology for enhanced scalp and hair vitality.

Elevai Labs has partnered with Yuva Biosciences to file two innovative patents aimed at enhancing hair and scalp care technology. The first patent addresses the combination of Elevai exosomes and Yuva's Y100 mitochondrial technology, potentially offering superior results. The second patent focuses on the use of lipid bilayer nanoparticles as a delivery system. These developments will be integrated into Elevai's S-Series Root Renewal System™, incorporating PREx™ and Y100 technologies, already endorsed by BosleyMD.

The Y100 technology, developed through Yuva's MitoGPT™ AI platform, is highly regarded for combating age-related hair and scalp issues. Elevai's strategic expansion includes full-scale marketing of the S-Series, anticipating significant interest from hair and scalp care professionals.

Elevai Labs, Inc. (NASDAQ: ELAB) has announced positive results from a clinical study of its Elevai enfinity™ topical exosome serum. The 12-week study, conducted on 29 participants aged 40-70 with mild to moderate facial photoaging and sensitive skin, showed the product to be safe and tolerable with significant improvements in various aspects of skin appearance.

The study, led by renowned dermatologist Dr. Zoe Draelos, assessed the twice-daily use of Elevai enfinity™ on facial firmness, skin tone, wrinkles, and smoothness. CEO Dr. Jordan R. Plews emphasized the importance of this rigorous study in validating the product's effectiveness. Elevai plans to publish the full study results soon and continues to prioritize scientific research as part of its commercial strategy for 2024 and beyond.

Elevai Labs Inc. (NASDAQ: ELAB) announced preliminary positive research data from a study with Dalhousie University, highlighting the potential of its proprietary exosome technology for skin health applications. The study revealed that ELEVAI exosomes™ contain over 800 proteins associated with wound healing, immunomodulation, and skin extracellular matrix remodeling.

Key findings include:

• ELEVAI exosomes™ demonstrated typical exosome morphology and diameter
• They were enriched with proteins related to ECM organization, hemostasis, and cellular stress response
• The protein profile was statistically significant and notably enriched compared to 54 previously published exosome protein datasets
• Proteins found may help prevent skin thinning, loss of elasticity, and wrinkle formation

Elevai plans to conduct further experiments to expand the research scope and explore broader applications such as bone regeneration, wound healing, and immune regulation.